ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Genomics and Proteomics"

  • Abstract Number: 0946 • ACR Convergence 2024

    Tissue Resident Monocyte-lineage Cells (TR-MC) Exist as Two Different Subpopulations

    Yidan Wang1, Jessica Maciuch2, Tyler Therron3, Carla Cuda2, Deborah Winter4 and Harris Perlman2, 1Northwestern University, Hanover Park, IL, 2Northwestern University, Chicago, IL, 3Northwestern University, Chicago, 4Northwestern University, Skokie, IL

    Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of peripheral monocytes (PM) is not sufficient to rescue disease in RA…
  • Abstract Number: 1589 • ACR Convergence 2024

    Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis

    Kristina Clark1, Corrado Campochiaro2, Philip Yee3, Emma Derrett-Smith4, Voon Ong5 and Christopher Denton6, 1University of Oxford, Oxford, United Kingdom, 2IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 3UCL, London, United Kingdom, 4University College London Division of Medicine, Birmingham, United Kingdom, 5University College London, London, England, United Kingdom, 6University College London, Northwood, United Kingdom

    Background/Purpose: Hallmark autoantibody reactivities predict different patterns of skin involvement and risk of internal organ involvement.  We have asked whether whole skin gene expression may…
  • Abstract Number: 1660 • ACR Convergence 2024

    Systemic Inflammation and Transcriptional Reprogramming Contribute to Progression to Active Rheumatoid Arthritis in ACPA+ Individuals

    Mark Gillespie1, Ziyuan He1, Adam Savage1, Pravina Venkatesan1, Marla Glass1, Lauren Okada2, Nhung Tran2, Yudong He2, Samir Rachid Zaim1, Padmapriyadarshini Ravisankar2, Christy Bennett1, Julian Reading2, Jessica Garber2, Palak Genge2, Veronica Hernandez2, Alexander Heubeck2, Erin Kawelo2, Upaasana Krishnan2, Kevin Lee2, Regina Mettey2, Blessing Musgrove2, Vaishnavi Parthasarathy2, Cole Phalen2, Charles Roll2, Tyanna Stuckey2, Morgan Weiss1, Claire Gustafson2, Qiuyu Gong2, Emma Kuan2, Tao Peng2, Lucas Graybuck2, Kristen Demoruelle3, Kristine Kuhn4, David Boyle5, Fan Zhang4, Thomas Bumol6, Ananda Goldrath2, Xiaojun Li1, V. Michael Holers7, Peter Skene1, Gary Firestein8, Kevin Deane9 and Troy Torgerson10, 1Allen Institute for Immunology, Seattle, WA, 2Allen Institute for Immunology, Seattle, 3University of Colorado Anschutz Medical Campus, Golden, CO, 4University of Colorado, Aurora, CO, 5UCSD, La Jolla, CA, 6Allen Institute for Immunology, San Diego, CA, 7University of Colorado, Denver, CO, 8University of California, San Diego, San Diego, CA, 9University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 10Allen Institute for Immunology, Enumclaw, WA

    Background/Purpose: Elevated levels of RA-associated autoantibodies (ACPA, RF) prior to the clinical onset of inflammatory arthritis (IA) define a state of risk for future development…
  • Abstract Number: 1762 • ACR Convergence 2024

    Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk

    Junjie Peng, Thomas McDonnell, Elizabeth Jury, Coziana Ciurtin and George Robinson, University College London, London, United Kingdom

    Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have…
  • Abstract Number: 1771 • ACR Convergence 2024

    Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics

    Mireia Lopez Corbeto1, yolanda Guillen2, Irene Bonafonte3, Nuria Palau4, Raül Tortosa4, Estefanía Moreno Ruzafa1, Antonio Julia5 and Sara Marsal6, 1Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, 2Imidomics, Inc, Barcelona, Spain, 3Berufserfahrung: Helmholtz Munich, Barcelona, Spain, 4Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, 5Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 6Vall Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…
  • Abstract Number: 1797 • ACR Convergence 2024

    Characterizing Memory T Cell Subsets Associated with SLE Etiopathogenesis

    Carol Nassar1, Rene Quevedo2, M. Teresa Ciudad2, Zoha Faheem3, Kieran Manion4, Carolina Munoz-Grajales5, Michael Kim6, Dafna Gladman7, Murray Urowitz8, Zahi Touma1, Tracy McGaha9 and Joan Wither6, 1University of Toronto, Toronto, ON, Canada, 2Princess Margaret Cancer Centre, Toronto, ON, Canada, 3UHN, Toronto, ON, Canada, 4Toronto Western Hospital, Toronto, ON, Canada, 5UHN/TWH, Toronto, ON, Canada, 6University Health Network, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8Self employed, Toronto, ON, Canada, 9University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with severe morbidity and mortality. Around 70% of SLE patients follow a relapsing-remitting pattern…
  • Abstract Number: 2096 • ACR Convergence 2024

    A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI

    Ignacio Rego-Perez1, Alejandro Duran-Sotuela2, Jorge Vazquez-Garcia2, Cristina Ruiz-Romero3, Valentina Calamia2, Carlota Fraga-Seijas4, Vanesa Balboa-Barreiro5, Sara Relaño2, María C. De Andrés2, Lucia Lourido2, Rocio Paz-Gonzalez2, Patricia Quaranta2, Patricia Fernández-Puente2, Nicola Veronese6, Natividad Oreiro7 and francisco J Blanco8, 1Instituto de Investigacion Biomedica de A Coruña-SERGAS, A Coruña, Spain, 2Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, 3INIBIC - CHUAC, A Coruña, Spain, 4INIBIC, A Coruña, Spain, 5Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, 6Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy, A Coruña, Spain, 7CHUAC, La Coruna, Galicia, Spain, 8INIBIC-University of A Coruña, A Coruña, Spain

    Background/Purpose: There is a need to design models that predict the risk of total joint replacement (TJR) in patients with knee osteoarthritis (OA). Our aim…
  • Abstract Number: 2418 • ACR Convergence 2024

    Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)

    Matthew Linnik1, Guilherme Rocha2, David Gemperline3, Ernst Dow3, Christoph Preuss3, Helen Masson4, Olivia Ellis4, Ana Accioly3, Maja Hojnik5, Kira Rubtsova1, Robert Benschop6, Mark Chambers7, Mark Genovese3 and Richard Higgs3, 1Eli Lilly, San Diego, CA, 2Eli Lilly, Indianapolis, IN, 3Eli Lilly and Co, Indianapolis, IN, 4Eli Lilly and Co, San Diego, CA, 5Eli Lilly and Co., Indianapolis, IN, 6Eli Lilly and Company, Indianapolis, IN, 7Eli Lilly, Zionsville, IN

    Background/Purpose: SLE flare is a clinically and regulatory relevant outcome, yet limited markers currently exist that predict its risk. We used baseline whole blood/serum samples…
  • Abstract Number: 1661 • ACR Convergence 2023

    Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin

    Kathryn Torok1, Ying-Ju Lai2, Zhongli Xu3, Anwesha Sanyal3, Giffin Werner3, Theresa Hutchins3, Claire Cheng3 and Wei Chen3, 1University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, 2University of Pittbsurgh, Pittsburgh, PA, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Recent single-cell RNA sequencing (scRNA seq) data has been generated across several tissues in autoimmune diseases, helping to understand the cellular and molecular underpinnings…
  • Abstract Number: 1762 • ACR Convergence 2023

    Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls

    JING SONG1, Cliff Rims1, Matthew Dufort1, Peter Linsley1, Eddie James2 and Jane Buckner2, 1Benaroya Research Institute, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA

    Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…
  • Abstract Number: 2342 • ACR Convergence 2023

    Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial

    Aida Santos da Costa1, Thomas Dörner2, Andrea Grioni1, Alexandre Avrameas1, Ulrike Sommer1, Rainer Hillenbrand1, Valeria De Luca1, Enrico Ferrero1, Andre Nogueira da Costa1, Isabelle Isnardi1 and Stephen J Oliver1, 1Novartis Pharma AG, Basel, Switzerland, 2Department of Medicine, Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum, Berlin, Germany

    Background/Purpose: Ianalumab (VAY736) is an afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
  • Abstract Number: 2540 • ACR Convergence 2023

    The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response

    Ismael Sanchez-Pareja1, Daniel Toro-Dominguez2, Carlos Perez-Sanchez3, Laura Muñoz-Barrera1, Tomás Cerdó1, Rafaela Ortega Castro4, Jerusalem Calvo5, Marta Rojas6, Pilar Font Ugalde1, Maria del Carmen Abalos-Aguilera7, Desiree Ruiz-Vilchez1, Christian Merlo-Ruiz1, Ivan Arias de la Rosa8, Mª Angeles Aguirre9, Eduardo Collantes Estévez10, Nuria Barbarroja11, Marta Alarcon-Riquelme12, Alejandro Escudero Contreras5 and Chary Lopez-Pedrera13, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 2GENYO, Granada, Spain, 3IMIBIC, Córdoba, Spain, 4Hospital Reina Sofía, Cordoba, Spain, 5Reina Sofia University Hospital, Córdoba, Spain, 6Hospital Universitario Reina Sofía, Cordoba, Spain, 7Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, 8IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, 9Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 10Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, 11University of Cordoba, Córdoba, Spain, 12Center for Genomics and Oncological Research (GENYO), Granada, Spain, 13IMIBIC - Reina Sofia Hospital, Córdoba, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a remarkably heterogeneous autoimmune disease whose clinical outcomes with disease-modifying antirheumatic drugs (DMARDs) remain unpredictable. The aim of this study…
  • Abstract Number: 2586 • ACR Convergence 2023

    A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis

    Peter C. Taylor1, Jenya Antonova2, Jennifer Geis3, Katharine Dilger3, David Chernoff4, Diana Abdueva3, Nancy Shadick5 and Michael Weinblatt6, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Compass Strategy and Research, Inc., San Francisco, CA, 3Aqtual Inc., Hayward, CA, 4Chernoff Consulting, Sausalito, CA, 5Brigham and Women's Hospital, Boston, MA, 6Harvard Medical School, Waban, MA

    Background/Purpose: Non-invasive differentiation of seropositive and seronegative rheumatoid arthritis (RA) from other conditions has been limited in the current practice. We aimed to evaluate the…
  • Abstract Number: 0024 • ACR Convergence 2023

    Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay

    Peter C. Taylor1, Jenya Antonova2, Jennifer Geis3, Katharine Dilger3, David Chernoff4, Diana Abdueva3, Nancy Shadick5 and Michael Weinblatt6, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Compass Strategy and Research, Inc., San Francisco, CA, 3Aqtual Inc., Hayward, CA, 4Chernoff Consulting, Sausalito, CA, 5Brigham and Women's Hospital, Boston, MA, 6Harvard Medical School, Waban, MA

    Background/Purpose: In rheumatoid arthritis [RA], synovial biopsies were shown to guide therapy selection1. However, biopsies require special training for clinicians and are semi-invasive for patients.…
  • Abstract Number: 0075 • ACR Convergence 2023

    Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)

    Zoya Qaiyum1, Michael Tang2 and Robert Inman2, 1Krembil Research Institute, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada

    Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. The…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology